IRIS
NATOLI, Clara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.066
EU - Europa 8.993
AS - Asia 6.866
SA - Sud America 904
Continente sconosciuto - Info sul continente non disponibili 867
AF - Africa 102
OC - Oceania 7
AN - Antartide 1
Totale 30.806
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.790
SG - Singapore 2.882
RU - Federazione Russa 2.707
CN - Cina 1.841
IT - Italia 1.125
IE - Irlanda 1.027
UA - Ucraina 914
SE - Svezia 792
FR - Francia 716
BR - Brasile 703
GB - Regno Unito 693
TR - Turchia 645
VN - Vietnam 623
DE - Germania 487
IN - India 281
FI - Finlandia 168
CA - Canada 130
HK - Hong Kong 124
BD - Bangladesh 122
AR - Argentina 64
PL - Polonia 63
AT - Austria 62
MX - Messico 62
BE - Belgio 52
JP - Giappone 52
IQ - Iraq 48
ES - Italia 41
NL - Olanda 37
CO - Colombia 35
ZA - Sudafrica 31
CZ - Repubblica Ceca 30
PK - Pakistan 28
SA - Arabia Saudita 23
EC - Ecuador 22
JM - Giamaica 22
KR - Corea 22
VE - Venezuela 22
PH - Filippine 20
CL - Cile 19
EG - Egitto 19
ID - Indonesia 19
UZ - Uzbekistan 18
EU - Europa 17
AE - Emirati Arabi Uniti 15
PY - Paraguay 13
AL - Albania 12
JO - Giordania 12
KE - Kenya 12
LT - Lituania 12
RO - Romania 12
GT - Guatemala 11
MA - Marocco 11
IL - Israele 10
PE - Perù 10
BO - Bolivia 9
HN - Honduras 9
LB - Libano 9
NP - Nepal 8
TH - Thailandia 8
TN - Tunisia 8
AU - Australia 7
CR - Costa Rica 7
DZ - Algeria 7
IR - Iran 7
MY - Malesia 7
TT - Trinidad e Tobago 7
UY - Uruguay 7
AZ - Azerbaigian 6
CH - Svizzera 6
DO - Repubblica Dominicana 6
NI - Nicaragua 6
OM - Oman 6
DK - Danimarca 5
GR - Grecia 5
SN - Senegal 5
EE - Estonia 4
ET - Etiopia 4
KW - Kuwait 4
PT - Portogallo 4
BG - Bulgaria 3
GE - Georgia 3
HR - Croazia 3
KG - Kirghizistan 3
MT - Malta 3
TW - Taiwan 3
AM - Armenia 2
BH - Bahrain 2
BS - Bahamas 2
CI - Costa d'Avorio 2
DM - Dominica 2
HU - Ungheria 2
KH - Cambogia 2
KZ - Kazakistan 2
MK - Macedonia 2
MM - Myanmar 2
QA - Qatar 2
SV - El Salvador 2
VG - Isole Vergini Britanniche 2
XK - ???statistics.table.value.countryCode.XK??? 2
AF - Afghanistan, Repubblica islamica di 1
Totale 29.936
Salva come PNG Salva come JPEG
Città #
Singapore 2.189
Chandler 1.479
San Jose 1.450
Jacksonville 1.171
Dublin 1.016
Ashburn 790
Dallas 577
Beijing 488
Princeton 466
Los Angeles 464
Southend 414
Council Bluffs 386
Izmir 378
Nanjing 342
Santa Clara 240
Wilmington 226
Ho Chi Minh City 201
The Dalles 196
Dearborn 191
New York 188
Ann Arbor 177
Cambridge 176
Buffalo 172
Altamura 167
Boardman 149
Chieti 142
Nanchang 127
Hanoi 126
Hong Kong 111
Tongling 111
Munich 103
Houston 102
Woodbridge 94
Moscow 82
São Paulo 75
Redondo Beach 70
Dong Ket 68
Rome 65
Orem 64
Shenyang 63
Chicago 60
Hebei 60
Phoenix 57
Kunming 54
Brooklyn 51
Tianjin 51
Brussels 49
Denver 47
Warsaw 47
Washington 47
Tokyo 46
Vienna 45
Atlanta 44
London 42
Jiaxing 40
Montreal 40
Milan 39
Norwalk 39
Columbus 37
Kimball 37
Nuremberg 37
Pescara 35
Frankfurt am Main 33
Mount Pleasant 33
San Francisco 32
Stockholm 32
Boston 30
Da Nang 29
Hyderabad 29
League City 29
Seattle 29
Helsinki 28
Chennai 26
Johannesburg 25
Mexico City 24
Changsha 23
Haiphong 23
Poplar 23
Brno 22
Falls Church 22
Hangzhou 22
Mumbai 22
Toronto 22
Belo Horizonte 21
Manchester 21
Silver Spring 21
Hefei 20
Rio de Janeiro 20
Kocaeli 19
Seoul 19
St Louis 19
Amsterdam 18
Baghdad 18
Kingston 17
San Mateo 17
Kansas City 16
Lanzhou 16
Naples 16
Shanghai 16
Tashkent 16
Totale 16.968
Salva come PNG Salva come JPEG
Nome #
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome 935
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer 912
Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer 837
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 452
45: L’UTILIZZO DELL’IMMUNOTERAPIA PER IL TRATTAMENTO DELL’ADENOCARCINOMA POLMONARE IN II LINEA: NIVOLUMAB VS PEMBROLIZUMAB 373
90K (Mac-2 BP) in human milk 250
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. 216
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 205
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 196
Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer 194
A multidisciplinary group for prostate cancer management: A single institution experience 194
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 194
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 191
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 186
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 180
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 178
90K protein in HIV infection: evidence of its release from peripheral blood mononuclear cells 176
90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells 176
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 176
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin 172
Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patients survival. 171
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 170
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 169
The 90K tumor associated antigen and clinical progression in human immunodeficiency virus infection 168
Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction 168
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 168
90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10^6 cells/L 167
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells 166
ABIRATERONE ACETATE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHEMOTHERAPY-NAIVE PATIENTS: AN ITALIAN MULTICENTER 'REAL-LIFE' 1-YEAR STUDY 165
Gli analoghi sintetici delle glicoamine come potenziali nuovi farmaci nella prevenzione delle metastasi 164
Epidermal Growth Factor Immunotherapy: Exploring the Effects of NB-UVB Exposure 164
A phase II study of cisplatin, epirubicin, vindesine chemotherapy and lonidamine in advanced nonsmall cell lung cancer 163
Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis 160
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 159
A novel serum test using interferon for early detection of tumor reccurrence in cancer patients after radical surgery. 158
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 156
Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alfa-interferon therapy in chronic HCV hepatitis patients 155
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer 154
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISTAPLIN, EPIRUBICIN AND VP – 16 FOR STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER 153
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 152
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 152
Purification and characterization of a 90 kDa protein releasedfrom human tumors and tumor cell lines 151
New Targets for Therapy in Pancreatic Cancer 150
Glicomimetici quali potenziali nuovi farmaci per la prevenzione delle metastasi. 149
Treatment of metastatic colorectal cancer patients 75 years old in clinical practice: A multicenter analysis 149
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 148
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 148
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 148
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. 147
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 145
Fulvestrant (FUL) 500 milligrams as endocrine therapy (ET) for hormone sensitive advanced breast cancer patients (pts). The Ful500 prospective observational trial 144
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study 143
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 141
BIOLOGICAL INDICATORS OF PROGNOSIS IN HUMAN CANCER: AN EMERGING ROLE FOR LECTIN GALACTOSIDE-BINDING SOLUBLE 3-BINDING PROTEIN (LGALS3BP) 141
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival 140
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases 140
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 140
Inhibition of tumor growth and angiogenesis by SP-2, an anti-LGALS3BP antibody 140
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study 139
TGF-β-1 increases 90K tumor associated antigen gene expression by increasing upstream regulatory factor binding to the minimal promoter. 138
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 138
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. 137
Chemotherapy preoperative for the management of breast cancer locally advanced 137
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. 137
Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient’s counselling – preliminary analysis of the INVIDIa study 137
90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection. 136
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 136
Expression of tumor associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen 134
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 134
Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey 134
Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A restrospective multicenter observational study. 134
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 134
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 133
Elevated serum levels of a 90,000 daltons tumor-associated antigen in cancer and in infection by human immunodeficiency virus (HIV). 133
Adherence to hormonal deprivation therapy in prostate cancer in clinical practice: a retrospective, single-centre study 133
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer 133
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study 132
Interleukin-30 Promotes Breast Cancer Growth and Progression 131
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag 131
A Flow cytometric study of early gastric cancer 130
Family history of cancer as surrogate predictor for immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: The FAMI-L1 study 130
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage 129
Principali effetti collaterali delle terapie mediche 129
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 129
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study 129
Alectinib induced regression of renal and hepatic cysts caused by crizotinib 129
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. 128
Unknown primary tumors 128
Tyrosine kinase inhibitors 128
Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation" 128
Prognostic value of 90K protein in HIV infection 126
Surgical treatment of adrenal metastases from non small cell lung cancer 126
Tumor-derived microvesicles: The metastasomes. 126
Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression 126
DNA ploidy and S-phase fraction in pulmonary carcinoids. 125
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A “snapshot” from clinical practice 125
Prognostic value of a novel circulating serum 90K antigen in breast cancer 124
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience 124
A real -life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second -line therapy 124
Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy 123
Totale 17.756
Salva come PNG Salva come JPEG
Categoria #
all - tutte 112.130
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 112.130
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.028 0 0 0 193 114 26 23 69 78 28 131 366
2022/20233.858 310 474 269 470 390 717 200 328 445 37 133 85
2023/20241.589 130 55 119 47 126 552 286 49 25 49 16 135
2024/20253.673 202 692 532 115 86 173 137 218 355 188 418 557
2025/202610.600 674 378 979 925 838 588 1.529 495 2.812 716 449 217
2026/20272.302 350 614 648 690 0 0 0 0 0 0 0 0
Totale 30.806